AstraZeneca Pharma India Receives CDSCO Permission For Enhertu Breast Cancer Indication

AstraZeneca Pharma India received CDSCO permission to import, market and distribute Enhertu for adjuvant treatment of adults with HER2-positive breast cancer with residual invasive disease after neoadjuvant therapy, subject to related statutory approvals. Context: extends the company’s ongoing oncology regulatory momentum.